Liver malignancies Liver neoplasms Liver tumors
Conditions
Interventions
Patients in this study will follow the CHASE protocol, which consists of a multidisciplinary approach aimed at optimizing the pre-, intra- and post-operative procedures surrounding elective liver surg
This accelerated recovery protocol focuses on three main factors: infusion management, pain management and truly minimally invasive surgery.
Sponsors
Maastricht Universitair Medisch Centrum +
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Signed informed consent; - Is >= 18 years
Exclusion criteria
Exclusion criteria: - ASA classification > 3; - Subjects undergoing rehepatectomy - Subjects who have limited mobility and/or need to be aided/assisted when mobilizing; - Subjects with a history of active pulmonary infection, any other active infection, any uncontrolled medical disease; - Subjects with (any form of) liver cirrhosis - Subjects with a contraindication for oral NSAIDs; - Subjects with a contraindication for spinal anesthesia; - Subjects requiring parenteral nutrition prior to surgery; - Subjects receiving an ostomy; - Subjects who experience complications preoperatively; - Subjects who are mentally incompetent, challenged or requiring aid with daily life activities.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of the successful and safe application of the accelerated recovery protocol for patients undergoing elective liver surgery. Success rate (feasibility) will be measured in length of hospital stay (LOS). Success is defined as discharge on POD1 after a minor liver resection and on POD2-3 after major liver resection discharge. Safety will be measured with rate of readmission and serious adverse events (Clavien Dindo >=3b) within 90 days postoperatively. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Postoperative complications within 90 days • Postoperative mortality within 90 days • Difference between achievement of functional recovery and actual discharge date • Patient satisfaction evaluation form • Demographic parameters • Disease related demographics • Comorbidities | — |
Countries
Netherlands
Contacts
Public ContactM.M.E. Coolsen
Maastricht Universitair Medisch Centrum +
Outcome results
None listed